**Significance of the influence of patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 polymorphism on non-alcoholic fatty liver disease**

Enas Mahmoud Foda1, Shereen Abu Bakr Saleh1, Moheb Shoraby Eskandaros2, Nashwa Nagy El-Khazragy3, Heba Mohamed Abu Bakr4, Yasmin Mohamed Massoud5, Ghada Abdelrahman Mohamed1

1Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt.

2 Departmentof General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt.

3 Departments of Clinical Pathology-Hematology and Genetics and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.

4Department of Internal Medicine, El Sahel Teaching Hospital, Cairo 11697, Egypt.

5Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt.

**Corresponding author:** Ghada Abdelrahman Mohamed, MD, Assist. Prof of Internal Medicine, Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt. ORCID: 0000-0003-0320-1011. Email: [ghadaabdelrahman@med.asu.edu.eg](file:///C%3A%5CUsers%5CMICROSOFT%5CDownloads%5Cghadaabdelrahman%40med.asu.edu.eg).

**DOI:****10.21608/ajgh.2024.313440.1061****.**

**Submission date:**18 August 2024.

**Revision date:** 26 September 2024.

**Acceptance date:** 20 October 2024.

**First online:** 26 October 2024.

**Abstract**

**Background:** Non-alcoholic fatty liver disease (NAFLD) is characterized by diffuse hepatocyte steatosis. The pathogenesis of NAFLD is not recognized. It has become apparent that genetic, environmental, and metabolic factors drive NAFLD. Moreover, earlier studies have observed that some polymorphisms raise the likelihood of NAFLD. Among these, the most robustly observed was the relationship between NAFLD risk and patatin-like phospholipase domain-containing 3 (PNPLA3). **Aim:** We aimed to assess the effect of the rs738409 polymorphism of the PNPLA3 gene (encoding I148m) on NAFLD. **Patients and Methods:** This study, which included 30 participants, was conducted with meticulous attention to detail and thoroughness: 20 patients with NAFLD and 10 healthy participants as a control group. Participants were diagnosed according to a liver biopsy taken during surgery from patients who were candidates for bariatric surgery and as part of a predonation assessment for candidates for donation in liver transplantation. Genotyping of the PNPLA3 gene variant (rs738409 C/G) was assessed using the TaqMan assay quantitative polymerase chain reaction in blood cells. **Results**: Considering the distribution of the PNPLA3 gene variant (rs738409 C/G), a greater prevalence of heterozygous rs738409 CG and homozygous rs738409 GG variants occurred in the NAFLD patients in contrast to the control group (*p* = 0.048). In addition, NAFLD patients with the homozygous GG variant had a higher incidence of hepatic fibrosis (*p* = 0.018). Furthermore, PNPLA3 gene polymorphism significantly predicted hepatic steatosis and fibrosis in NAFLD patients (*p* = 0.033 and *p* < 0.001, respectively). **Conclusion:** The PNPLA3 rs738409 polymorphism is significantly associated with the susceptibility and severity of non-alcoholic fatty liver disease.

***Keywords****: Non-alcoholic Fatty Liver Disease**; Patatin-Like Phospholipase Domain-Containing Protein 3; rs738409; Mean Platelet Volume; Neutrophil to Lymphocyte Ratio.*

**Introduction**

Non-alcoholic fatty liver disease (NAFLD) is characterized by disseminated hepatocyte steatosis, excluding extreme alcohol consumption and other hepatic diseases [1]. It affects approximately 32.4% of the general population [2,3]. NAFLD has a broad spectrum extending from non-alcoholic fatty liver, which does not cause significant health risks, to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis, and finally hepatocellular carcinoma (HCC) [4,5]. Further, NAFLD is implicated in 36% of liver-related mortality, especially with progressive clinical forms of the disease [6].

The pathogenesis of NAFLD is not fully recognized [7]. Recently, NAFLD has been considered a multifactorial disease driven by genetic, environmental, and metabolic factors [8]. Substantial inter-individual variations exist in the progression and disease severity in NAFLD cases, and they share the same environmental and metabolic risk factors [9]. In addition, inter-ethnic variations and familial clustering point to the substantial impact of genetic factors in the pathophysiology of NAFLD [10]. Moreover, earlier studies have detected that some polymorphisms raise the risk of NAFLD [11-13]. Among these, the most robustly observed is the relationship between NAFLD risk and the patatin-like phospholipase domain-containing 3 (PNPLA3) gene [11]. The PNPLA3 is a transmembrane protein of 481 amino acids, primarily expressed in hepatocytes, skin, and adipocytes [14,15]. In addition, it is a lipoatrophic protein that influences hepatic fat metabolism through triacylglycerol lipase and acylglycerol O-acyltransferase activities. The nonsynonymous gene variant (C > G, rs738409), where isoleucine is replaced at position 148 with methionine (PNPLA3-I148M), was regarded as a significant genetic predisposing factor for NAFLD and NASH [16].

The exact mechanism and outcomes of PNPLA3-I148M are not yet comprehensively known. Nevertheless, this variant can produce both a loss and gain of function. The loss of function occurs by impairing lipolytic activity, which enhances triglyceride deposition [17]. Additionally, it was suggested that this variant promotes intracellular lipid accumulation through its effects on the excretion of ApoB-containing lipoproteins and esterification of very low-density lipoproteins [18]. Moreover, this variant impaired triglyceride hydrolysis in hepatocytes [19]. In addition, PNPLA3 encodes adipo-nutrients found on the lipid droplets and endoplasmic reticulum in hepatocytes, which may be another process by which the PNPLA3-I148M mutation results in increased hepatic triglyceride content [20]. Evidence also indicates increased hepatic triglyceride synthesis by promoting the function of lysophosphatidic acid acyltransferase through the gain of function caused by this variant [21]. Moreover, this mutation enhances the development of hepatic fibrosis through impaired retinyl-palmitate lipase activity, upregulating proinflammatory cytokines, c-Jun N-terminal kinase (JNK), and activator protein-1 (AP-1) and enhancing matrix metalloproteinase expression [22]. Other authors have further replicated these findings, as the PNPLA3-I148M variant caused mitochondrial failure *via* the deposition of cholesterol by decreasing the ABCG1 protein expression and preventing cholesterol efflux, causing the progression of hepatic fibrosis [23]. Hence, we aim to assess the effect of the PNPLA3 (rs738409) gene polymorphism on NAFLD.

**Patients and Methods**

This study involved 30 participants, 20 NAFLD cases, and 10 normal individuals as a control group enrolled from the Internal Medicine and Surgical departments at Ain Shams University Hospitals from December 2021 to February 2023. Participants were diagnosed according to a liver biopsy taken during surgery from candidates for bariatric surgery (NAFLD cases) and as part of a predonation assessment for candidates for donation for liver transplantation as a control.

Patients 18 years and older were involved in the research, excluding those with hepatic diseases of other known aetiologies, such as autoimmune hepatitis, viral hepatitis, and Wilson’s disease. In addition, those with alcoholic liver disease, medication use known to induce hepatic steatosis or immunosuppression, and a history of malignancy or hematological diseases or current infection were also excluded. All participants underwent the following:

* A complete blood count and calculation of the neutrophil to lymphocyte ratio (NLR) and mean platelet volume (MPV) [24],
* Genotyping of the PNPLA3 gene variant (rs738409 C/G) using the TaqMan assay qPCR in blood cells. Per the manufacturer's instructions, DNA was extracted from all participants using a Genomic whole-blood extraction kit (Puregene, USA). The DNA was dissolved in a TE buffer, and the DNA purity and concentration were determined using spectrophotometry. Real-time PCR was applied to detect single nucleotide polymorphisms in the PNPLA3 gene (rs738409), and the allelic discrimination of the PNPLA3 polymorphisms was investigated using the TaqMan assay,
* Abdominal ultrasonography,
* Liver biopsy specimens were analyzed using the scoring system in Table 1.

Tab 1. The clinical research network system for scoring activity and fibrosis in NAFLD [25]

|  |  |  |
| --- | --- | --- |
| **The grade of steatosis**  | **Hepatic lobular inflammation**  | **Hepatocellular ballooning**  |
| 0 = < 5% | 0 = None | 0 = None |
| 1 = 5-33% | 1 = < 2 | 1 = Few ballooned cells |
| 2 = 34-66% | 2 = 2-4 | 2 = Many ballooned cells |
| 3 = > 66% | 3 = > 4 |  |

**Statistical analysis**

Statistical analysis was conducted using the student t-test, Chi-square test, Person's correlation coefficient, regression coefficient, and Analysis of variance [ANOVA] test by SPSS V25. Data were presented as mean ± standard deviation, median and range, or number and percentage. P-value ≤ 0.05 was considered significant.

**Results**

The present research was performed on 30 participants. They were categorized into two groups following histopathology. The NAFLD group comprised 20 patients, and the control group comprised 10 healthy participants. Table 2 lists the clinical data of the study participants. NAFLD patients had higher BMI and MPV than the control group (*p* < 0.001 and *p* = 0.012, Table 2). In addition, table 2 demonstrates the differences in ultrasound and liver biopsy findings between the study groups (*p* ≤ 0.05, Table 2). No statistically significant correlation was noted between the NLR and MPV, liver enzymes, lipid panel, body mass index (BMI), the existence of fatty liver on ultrasound, and hepatic steatosis and fibrosis in liver biopsy (*p* ≥ 0.05, Supp. table 1). A significant correlation existed between the BMI and the existence of fatty liver on ultrasound and steatosis and fibrosis in liver biopsy (*p* = 0.04, 0.022, and 0.035, respectively, Supp. table 2).

Tab 2. Study participant characteristics

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **NAFLD (*n*=20)** | **Control (*n*=10)** | ***P* value** |
| Sex | Male | 12 (60%) | 5 (50%) | 0.602 |
| Female  | 8 (40%) | 5 (50%) |
|  | **Mean ± SD** | **Mean ± SD** |  |
| Age (years) | 28.75±5.26 | 28.50±6.55 | 0.911 |
| Body mass index  | 33.50±5.30 | 22.90±2.18 | <0.001 |
| Total leucocytes count (x103)/µL | 6.77±2.23 | 6.51±1.95 | 0.753 |
| Hemoglobin (g/dL) | 13.51±1.33 | 13.83±1.91 | 0.596 |
| Platelets count (x103)/µL | 269.45±80.81 | 267±48.78 | 0.931 |
| Aspartate aminotransferase (U/mL) | 21 (10.6 – 63.0) | 15 (13.0 – 28.0) | 0.42 |
| Alanine aminotransferase (U/mL) | 21 (8 – 90) | 15 (9.0 – 33.0) | 0.28 |
| Serum albumin (mg/dL) | 4.49±0.45 | 4.41±0.42 | 0.641 |
| Total bilirubin (mg/mL) | 0.62 (0.3 – 1.6) | 0.5 (0.37 – 1.09) | 0.603 |
| Direct bilirubin (mg/mL) | 0.2 (0.1 – 0.4) | 0.2 (0.1 – 0.4) | 0.81 |
| International normalized ratio  | 1.0 (0.9 – 1.2) | 1.0 (0.8 – 1.04) | 0.14 |
| Blood urea nitrogen (mg/mL) | 14.50±4.75 | 14.70±4.21 | 0.911 |
| Creatinine (mg/mL) | 0.89±0.14 | 0.78±0.13 | 0.050 |
| Total cholesterol (mg/mL) | 196.50 ±37.68 | 174.60±22.32 | 0.103 |
| High-density lipoprotein (mg/mL) | 38.90±9.06 | 45.10±9.04 | 0.088 |
| Triglycerides (mg/mL) | 160.05±66.38 | 112.60±52.41 | 0.059 |
| LDL-Cholesterol (mg/mL) | 111.35±20.64 | 106.30±21.56 | 0.539 |
| Fasting blood glucose (mg/mL) | 82.95±10.68 | 86.20±8.32 | 0.408 |
| 2 hours PP blood glucose (mg/mL) | 100.35±15.70 | 107.60±16.72 | 0.253 |
| HbA1C | 5.39±0.39 | 5.45±0.37 | 0.693 |
| Mean platelet volume (fL) | 10.39±1.10 | 9.14±1.39 | 0.012 |
| Neutrophil to lymphocyte ratio | 1.47±0.28 | 1.49±0.38 | 0.863 |
| Fatty liver in ultrasound | Grade 0 | 3 (15%) | 10 (100%) | <0.001 |
| Grade I | 12 (60) | 0 |
| Grade II | 4 (20%) | 0 |
| Grade III | 1 (5%) | 0 |
| Hepatic steatosis | Grade I | 18 (90%) | 0 | - |
| Grade II | 2 (10%) | 0 |
| Lobular inflammation  | No | 3 (15%) | 9 (90%) | 0.002 |
| Mild | 12 (60%) | 1 (10%) |
| Moderate  | 1 (5%) | 0 |
| Severe  | 4 (20%) | 0 |
| Hepatocyte ballooning  | No | 3 (15%) | 10 (100%) | <0.001 |
| Mild | 7 (35%) | 0 |
| Severe  | 10 (50%) | 0 |
| Hepatic fibrosis  | No  | 3 (15%) | 10 (100%) | <0.001 |
| Yes  | 17 (85%) | 0 |

 Considering the distribution of the PNPLA3 gene variant (rs738409 C/G), a greater prevalence of heterozygous rs738409 CG and homozygous rs738409 GG variants occurred in the NAFLD patients in contrast to the control group (*p* = 0.048, Table 3). Table 4 shows the grades of hepatic steatosis, hepatic fibrosis, and hepatocyte ballooning in NAFLD cases according to the PNPLA3 gene variant status. Patients with NAFLD with the homozygous GG variant had a higher incidence of hepatic fibrosis (*p* = 0.018). However, no significant variation was found regarding hepatocyte ballooning and hepatic steatosis (*p* ≥ 0.05). However, those with the homozygous rs738409 GG variant had grade II steatosis with a higher prevalence of hepatocyte ballooning. Further, no significant variations occurred in the NLR, ALT, AST, total cholesterol, LDL cholesterol, and triglyceride values in NAFLD cases according to the PNPLA3 gene rs738409C/G variant status (*p* ≥ 0.05, Supp. table 3). At the same time, MPV was significantly different between the groups (*p* = 0.023, Supp. Table 3).

Tab 3. Distribution of the PNPLA3 polymorphism among NAFLD and control groups

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PNPLA3 polymorphism** | **Total participants(*n*=30)**  | **NAFLD (*n*=20)** | **Control (*n*=10)** | ***P* value** |
|  | ***n* (%)** | ***n* (%)** | ***n* (%)** |  |
| Homozygous CC | 10 (33.3%) | 4 (20%) | 6 (60%) | 0.048 |
| Heterozygous CG | 9 (30%) | 7 (35%) | 2 (20%) |
| Homozygous GG | 11 (36.7%) | 9 (45%) | 2 (20%) |

Tab 4. The hepatic steatosis, hepatocellular ballooning, and hepatic fibrosis in NAFLD patients according to the PNPLA3 polymorphism

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Homozygous CC** | **Heterozygous CG** | **Homozygous GG** | ***P* value** |
| Hepatic steatosis | Grade I | 4 (100%) | 7 (100%) | 7 (77.78%) | 0.155 |
| Grade II | 0 | 0 | 2 (22.22%) |
| Hepatocyte ballooning | No | 0 | 3 (42.86%) | 0 | 0.126 |
| Mild | 1 (25%) | 2 (28.57%) | 4 (44.44%) |
| Severe | 3 (75%) | 2 (28.57%) | 5 (55.56%) |
| Hepatic fibrosis | No | 4 (100%) | 3 (42.86%) | 0 | 0.018 |
| Yes | 0 | 4 (57.14%) | 9 (100%) |

Table 5 shows that hepatic steatosis correlated positively with PNPLA3 gene polymorphism and BMI (*p* = 0.033 and *p* < 0.001, respectively). Additionally, they were predictors for hepatic steatosis (*p* = 0.033 and *p* < 0.001, respectively, Supp. Table 4). Table 6 shows that hepatic fibrosis correlated positively with PNPLA3 gene polymorphism, BMI, and total cholesterol (*p* < 0.001, *p* < 0.001, and *p* = 0.049, respectively). However, PNPLA3 gene polymorphism was the only predictor for hepatic fibrosis (*p* < 0.001, Supp. Table 5).

Tab 5. Correlations between hepatic steatosis and other studied parameters

|  |  |
| --- | --- |
|  | **Hepatic steatosis**  |
| **r** | ***P* value** |
| Neutrophil to lymphocyte ratio | 0.209 | 0.377 |
| Mean platelet volume | 0.168 | 0.479 |
| Total cholesterol | 0.436 | 0.055 |
| LDL-Cholesterol  | 0.246 | 0.295 |
| Body mass index | 0.863 | <0.001 |
| PNPLA3 gene polymorphism  | 0.391 | 0.033 |

Tab 6. Correlations between hepatic fibrosis and other studied parameters

|  |  |
| --- | --- |
|  | **Hepatic fibrosis** |
| **r** | ***P* value** |
| Neutrophil to lymphocyte ratio | 0.094 | 0.623 |
| Mean platelet volume | 0.127 | 0.503 |
| Total cholesterol  | 0.363 | 0.049 |
| LDL-Cholesterol  | 0.067 | 0.724 |
| Body mass index | 0.642 | <0.001 |
| PNPLA3 gene polymorphism  | 0.689 | <0.001 |

**Discussion**

The first genome-wide association study (GWAS) regarding NAFLD found that the allele of PNPLA3rs738409 is significantly correlated with hepatic steatosis and inflammation [26]. This finding gave new insight into the pathogenesis of NAFLD. Since then, knowledge regarding the genetic constituents of NAFLD has substantially increased. Several studies have reported that this variant leads to the development of NAFLD by increasing triglyceride production and deposition in hepatocytes, increasing the risk of hepatic hepatocyte ballooning, steatosis, and lobular inflammation [27,28]. Furthermore, PNPLA3 rs738409 polymorphism is strongly linked to NASH, cirrhosis, HCC, and death [29-31]. The impact of this polymorphism is observed even in individuals with lean NAFLD [32].

The current study detected a greater prevalence of heterozygous rs738409 CG and homozygous rs738409 GG PNPLA3 gene variants in the NAFLD group compared to the controls. Additionally, NAFLD cases with heterozygous rs738409 CG and homozygous rs738409 GG PNPLA3 gene variants had a higher incidence of hepatic fibrosis compared to the homozygous rs738409 CC gene variant. Furthermore, PNPLA3 rs738409 polymorphism was a significant predictor for both hepatic steatosis and fibrosis. The results align with a meta-analysis consisting of 16 studies that examined 2,124 patients and detected that the homozygous PNPLA3rs738409 GG had a 73% higher hepatic fat content in comparison to the homozygous rs738409 CC polymorphism. In addition, rs738409 GG had a greater risk of developing fibrosis than homozygous CC [16].

In agreement with the current study, case-control research, including the genomic data of 2,950 NAFLD patients and 12,907 healthy controls, detected that the frequency of the PNPLA3 rs738409 GG allele was higher in NAFLD patients than in the control group. Furthermore, the PNPLA3 rs738409 GG and GC variants had more NAFLD patients than the PNPLA3 rs738409 CC variant (19.9% *vs* 16%). In addition, the PNPLA3 rs738409 GG allele was an independent risk factor for NAFLD [33].

In agreement with the current results, a GWAS by Anstee *et al*. reported that the PNPLA3rs738409 variant is a risk factor for the full pathological spectrum of NAFLD [28]. Another study found that the BMI, serum triglyceride, and AST levels were risk factors for NAFLD [34]. In addition, a meta-analysis consisting of 20 studies recorded a significant correlation between NAFLD susceptibility and PNPLA3 rs738409 polymorphism [20]. However, in contrast to our results, Li *et al*. [35] detected no correlation between hepatic steatosis and PNPLA3 rs738409 gene polymorphism.

Many studies have confirmed a strong relationship between metabolic syndrome and the grade of fibrosis and steatosis in NAFLD [36,37]. In agreement with earlier studies [33,34,38], NAFLD patients had higher BMI values than the control group. Moreover, a strong association was detected between the BMI and hepatic steatosis and fibrosis in liver biopsy.

Substantial evidence suggests that stimulating the immune system with proinflammatory mediators secreted by visceral adipose tissue is crucial to disease severity and progression. In addition, intrahepatic lipids are implicated in inducing oxidative stress, triggering portal and lobular inflammation, and characterizing the severe histological forms of the disease [39]. Further, accumulating data supports that the NLR is a simple marker in estimating the NAFLD severity [40]. In contrast to our results, Lesmana *et al*. [38] observed that cases with moderate to severe steatosis had a greater NLR than patients with mild steatosis. Additionally, Yilmaz *et al*. [41] noted that cases with NASH had a greater NLR than controls. However, in agreement with the present results, a large cohortstudy found that the NLR is unrelated to fibrosis and inflammation in NAFLD [42].

In agreement with an earlier study [43], NAFLD patients had a greater MPV than the control group. However, MPV was not statistically different between the NAFLD group and controls, nor was it a predictive factor for NAFLD in another study [34].

A significant strength of the present research is evaluating hepatic disease with biopsy-proven NAFLD, the golden standard for assessing liver disease severity. However, the present study is restricted by the small sample size. According to the current results, PNPLA3 genotyping may improve risk stratification and prognostication and allow for the prioritization of intensive interventions in NAFLD patients [44]. Additionally, with this knowledge, it has become possible to apply its effects on NAFLD into clinical applications, such as innovative drugs, and discover potential targets to treat the disease [45,46]. In this context, antisense oligonucleotide-mediated silencing of the PNPLA3 genewas investigated in a mouse model. Notably, there was a decline in the NAFLD activity score, hepatic inflammation, steatosis, and fibrosis grade [47].

**Conclusions**

The PNPLA3 rs738409 polymorphism is significantly associated with the susceptibility and severity of non-alcoholic fatty liver disease.

**Footnotes.**

The peer reviewers were Amr Shaban Hanafy (professor of internal medicine, gastroenterology, hepatology unit), Marwa Shabana (assistant professor of clinical pathology), and Amany Mohamed (Assistant professor of family medicine).

**E- Editor:** Salem Youssef Mohamed, Osama Ahmed Khalil, Amany Mohammed.

**Copyright ©.** This open-access article is distributed under the Creative Commons Attribution License (CC BY). It may be used, distributed, or reproduced in other forums, provided the original author(s) and the copyright owner(s) are credited. The original publication in this journal must be cited according to accepted academic practice.

**Disclaimer:** The authors' claims in this article are solely their own and do not necessarily represent their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product evaluated in this article or its manufacturer's claim is not guaranteed or endorsed by the publisher.

**Ethical approval:** All procedures involving human participants followed the institutional and national research committee's moral standards, the 1964 Helsinki Declaration, and its later amendments or comparable ethical standards. All authors declare that consent was obtained from the patients (or other approved parties) to publish this study.

The Clinical Research Ethics Committee of the Faculty of Medicine, Ain Shams University (**FMASU MD 284/2018**) authorized the study protocol. All contributors signed a written informed agreement.

**Data and materials availability:** The datasets used or analyzed during the current study are available from the corresponding author upon reasonable request.

**Competing interests**: The authors declare that they have no competing interests.

**Funding**: This study had no funding from any resource.

This work was done according to the **STROBE** guidelines.

**Authors’ contributions**

Enas Mahmoud Foda and Shereen Abu Bakr Saleh conceived the research concept. At the same time, Moheb Shoraby Eskandaros, Nashwa Nagy El-Khazragy, and Heba Mohamed Abu Bakr conducted the clinical examinations and monitored the patients. Yasmin Mohamed Massoud and Ghada Abdelrahman Mohamed collaborated to gather laboratory data. All authors actively participated in analyzing and interpreting the patient information and composing the manuscript. All authors thoroughly reviewed and approved the final version of the manuscript.

**References**

1. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2020;5(8):739-752. doi:10.1016/S2468-1253(20)30077-7
2. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0
3. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States for 2016-2030. *J Hepatol*. 2018;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036
4. Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. *Hepatology*. 2020;72(5):1605-1616. doi:10.1002/hep.31173
5. Yip TC, Vilar-Gomez E, Petta S, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. *Hepatology*. 2023;77(4):1404-1427. doi:10.1002/hep.32774
6. Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. Attributable Fractions of Non-alcoholic Fatty Liver Disease for Mortality in the United States: Results from the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. *Hepatology*. 2020;72(2):430-440. doi:10.1002/hep.31040
7. Ganji SH, Kashyap ML, Kamanna VS. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. *Metabolism*. 2015;64(9):982-990. Doi: 10.1016/j.metabol.2015.05.002
8. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology*. 2020;158(7):1999-2014.e1. Doi: 10.1053/j.gastro.2019.11.312
9. Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci*. 2016;17(5):774. Published 2016 May 20. doi:10.3390/ijms17050774
10. Rich NE, Oji S, Mufti AR, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16(2):198-210.e2. Doi: 10.1016/j.cgh.2017.09.041
11. Balcar L, Semmler G, Oberkofler H, et al. PNPLA3 is the dominant SNP linked to liver disease severity at the time of first referral to a tertiary center. *Dig Liver Dis*. 2022;54(1):84-90. Doi: 10.1016/j.dld.2021.06.015
12. Gao F, Zheng KI, Chen SD, et al. Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. *Clin Transl Gastroenterol*. 2021;12(3): e00321. Published 2021 Mar 10. doi:10.14309/ctg.0000000000000321
13. Huh Y, Cho YJ, Nam GE. Recent Epidemiology and Risk Factors of non-alcoholic Fatty Liver Disease. *J Obes Metab Syndr*. 2022;31(1):17-27. doi:10.7570/jomes22021
14. Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte. 2019 Dec;8(1):201-208. Doi: 10.1080/21623945.2019.1607423. PMID: 31062641; PMCID: PMC6768214.
15. Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. *Expert Opin Ther Targets*. 2021;25(12):1033-1043. doi:10.1080/14728222.2021.2018418
16. Sookoian S, Pirola CJ. Meta-analysis of the influence of the I148M variant of patatin-like phospholipase domain containing 3 genes (PNPLA3) on the susceptibility and histological severity of non-alcoholic fatty liver disease. *Hepatology*. 2011;53(6):1883-1894. doi:10.1002/hep.24283
17. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with non-alcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem*. 2010;285(9):6706-6715. doi:10.1074/jbc.M109.064501
18. Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. *J Hepatol*. 2012;57(6):1276-1282. Doi: 10.1016/j.jhep.2012.07.030
19. Luukkonen PK, Nick A, Hölttä-Vuori M, et al. The human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. *JCI Insight*. 2019;4(16): e127902. Published 2019 Aug 22. Doi: 10.1172/jci.insight.127902
20. Zhao Y, Zhao W, Ma J, Toshiyoshi M, Zhao Y. Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to non-alcoholic fatty liver disease: A meta-analysis of twenty studies. *Medicine (Baltimore)*. 2023;102(10): e33110. doi:10.1097/MD.0000000000033110
21. Green CJ, Johnson D, Amin HD, et al. Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line. *Am J Physiol Endocrinol Metab*. 2015;309(6): E511-E522. doi:10.1152/ajpendo.00594.2014
22. Bruschi FV, Claudel T, Tardelli M, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. *Hepatology*. 2017;65(6):1875-1890. doi:10.1002/hep.29041
23. Gou Y, Wang L, Zhao J, et al. PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction. *Int J Mol Sci*. 2023;24(11):9681. Published 2023 Jun 2. doi:10.3390/ijms24119681
24. Abdel-Razik A, Mousa N, Shabana W, et al. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of non-alcoholic steatohepatitis in NAFLD patients: a multicentric study. *Eur J Gastroenterol Hepatol*. 2016;28(1): e1-e9. doi:10.1097/MEG.0000000000000486
25. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi: 10.1002/hep.20701.
26. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to non-alcoholic fatty liver disease. *Nat Genet*. 2008;40(12):1461-1465. doi:10.1038/ng.257
27. Mullins VA, Bresette W, Johnstone L, Hallmark B, Chilton FH. Genomics in Personalized Nutrition: Can You "Eat for Your Genes"? *Nutrients*. 2020;12(10):3118. Published 2020 Oct 13. doi:10.3390/nu12103118
28. Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterized cohort. *J Hepatol* 2023; 78(5):1085-1086. Doi: 10.1016/j.jhep.2020.04.003
29. Dhar D, Loomba R. Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH. *Hepatology*. 2021;73(4):1248-1250. doi:10.1002/hep.31735
30. Kim HS, Xiao X, Byun J, et al. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity with Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. *JAMA Netw Open*. 2022;5(10): e2234221. Published 2022 Oct 3. doi:10.1001/jamanetworkopen.2022.34221
31. Xia M, Ma S, Huang Q, et al. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. *Aliment Pharmacol Ther*. 2022;55(6):705-721. doi:10.1111/apt.16772
32. Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. *Hepatology*. 2021;74(4):2241-2250. doi:10.1002/hep.32047
33. Oh S, Lee J, Chun S, et al. Interaction between the *PNPLA3* Gene and Nutritional Factors on NAFLD Development: The Korean Genome and Epidemiology Study. *Nutrients*. 2022;15(1):152. Published 2022 Dec 28. doi:10.3390/nu15010152
34. Tuzer C, Sertbas Y, Duman E, et al. The role of mean platelet volume in non-alcoholic fatty liver disease without cardiovascular comorbidities, obesity, and diabetes mellitus. *Eur J Gastroenterol Hepatol*. 2021;33(9):1222-1228. doi:10.1097/MEG.0000000000002189
35. Li X, Zhao Q, Wu K, Fan D. I148M variant of PNPLA3 confer increased risk for non-alcoholic fatty liver disease not only in European population, but also in Chinese population. *Hepatology*. 2011;54(6):2275. doi:10.1002/hep.24567
36. Shi FY, Gao WF, Tao EX, Liu HQ, Wang SZ. Metabolic syndrome is a risk factor for nonalcoholic fatty liver disease: evidence from confirmatory factor analysis and structural equation modeling. *Eur Rev Med Pharmacol Sci*. 2016;20(20):4313-4321.
37. Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease - Where do we stand?. *World J Gastroenterol*. 2016;22(32):7236-7251. doi:10.3748/wjg. v22.i32.7236
38. Lesmana CRA, Kencana Y, Rinaldi I, et al. Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). *Diabetes Metab Syndr Obes*. 2022; 15:15-22. Published 2022 Jan 5. doi:10.2147/DMSO.S330526
39. Parthasarathy G, Revelo X, Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. *Hepatol Commun*. 2020;4(4):478-492. Published 2020 Jan 14. doi:10.1002/hep4.1479
40. WenYi J, Ting Q, PiaoPiao Y, JinMing W. Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease. *Turk J Gastroenterol*. 2022;33(1):53-61. doi:10.5152/tjg.2022.20715
41. Yilmaz H, Yalcin KS, Namuslu M, et al. Neutrophil-Lymphocyte Ratio (NLR) Could Be a Better Predictor than C-reactive Protein (CRP) for Liver Fibrosis in Non-alcoholic Steatohepatitis (NASH). *Ann Clin Lab Sci*. 2015;45(3):278-286.
42. Kara M, Dogru T, Genc H, et al. The neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol*. 2015;27(10):1144-1148. doi:10.1097/MEG.0000000000000405
43. Karaoğullarindan Ü, Üsküdar O, Odabaş E, et al. Is mean platelet volume a simple marker of non-alcoholic fatty liver disease? *Indian J Gastroenterol*. 2023;42(2):219-225. doi:10.1007/s12664-022-01330-8
44. Chen VL, Oliveri A, Miller MJ, et al. PNPLA3 Genotype and Diabetes Identify Patients with non-alcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis. *Gastroenterology*. 2023;164(6):966-977.e17. Doi: 10.1053/j.gastro.2023.01.040
45. Pirola CJ, Sookoian S. Personalized medicine in non-alcoholic fatty liver disease. *Clin Mol Hepatol*. 2022;28(4):935-938. doi:10.3350/cmh.2022.0175
46. Sookoian S, Pirola CJ. Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response. *Clin Mol Hepatol*. 2023;29(Suppl): S184-S195. doi:10.3350/cmh.2022.0318
47. Lindén D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates non-alcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. *Mol Metab*. 2019; 22:49-61. Doi: 10.1016/j.molmet.2019.01.013.